Gram-Negative Bacterial Infections Therapeutic Pipeline Reviewed in Global Markets Direct Study Available at MarketPublishers.com
04 Jul 2013 • by Natalie Aster
LONDON – Gram-negative bacteria, such as Klebsiella, Pseudomonas aeruginosa, Acinetobacter and E. coli., along with many other less common bacteria, cause infections including pneumonia, wound or surgical site infections, bloodstream infections and meningitis in healthcare settings. Gram-negative bacteria are resistant to multiple drugs and are increasingly resistant to most available antibiotics. These bacteria have built-in abilities to find new ways to be resistant and can pass along genetic materials that allow other bacteria to become drug-resistant as well.
The discovery of new drugs active against hospital-acquired gram-negative bacteria is essential to prevent a future medical and social catastrophe. An important strategy to promote drug discovery will be the development of focused cooperation activities between academic institutions and small pharmaceutical companies.
Topical market research study “Gram-Negative Bacterial Infections – Pipeline Review, H1 2013” elaborated by Global Markets Direct provides accurate and comprehensive insights into the therapeutic development for gram-negative bacterial infections. The report particularly features:
- description of the global therapeutic scenario for gram-negative bacterial infections;
- review of the gram-negative bacterial infections products under development by companies and universities/research institutes;
- coverage of products based on various stages of development ranging from discovery till registration stages;
- feature on pipeline projects on the basis of monotherapy and combined therapeutics;
- review of the gram-negative bacterial infections pipeline based on route of administration and molecule type;
- insights into key discontinued pipeline projects;
- most recent news and deals relating to the products.
Gram-Negative Bacterial Infections – Pipeline Review, H1 2013
Published: June, 2013
The Market Price: US$ 2,000.00
Other Diseases Therapeutic Pipeline Reviews H1 2013 by Global Markets Direct Include:
- Metastatic Breast Cancer – Pipeline Review, H1 2013
- Inflammation – Pipeline Review, H1 2013
- Chemotherapy Induced Nausea and Vomiting – Pipeline Review, H1 2013
- Post-Operative Pain – Pipeline Review, H1 2013
- Seasonal Allergic Rhinitis – Pipeline Review, H1 2013
More topical research studies by the publisher can be found at Global Markets Direct page.